FG

FibroGen

- NASDAQ:FGEN
Last Updated 2024-04-23

LinkedIn Profile

Access FibroGen historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:fgen 163793 Apr 21st, 2024 12:00AM FibroGen, Inc. 15K 428.00 Open Apr 20th, 2024 11:27PM Apr 20th, 2024 11:27PM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 20th, 2024 12:00AM FibroGen, Inc. 15K 428.00 Open Apr 19th, 2024 11:24PM Apr 20th, 2024 04:59PM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 19th, 2024 12:00AM FibroGen, Inc. 15K 429.00 Open Apr 18th, 2024 11:31PM Apr 18th, 2024 11:31PM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 18th, 2024 12:00AM FibroGen, Inc. 15K 430.00 Open Apr 17th, 2024 11:39PM Apr 18th, 2024 06:19PM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 17th, 2024 12:00AM FibroGen, Inc. 15K 431.00 Open Apr 16th, 2024 11:21PM Apr 17th, 2024 02:44PM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 16th, 2024 12:00AM FibroGen, Inc. 15K 431.00 Open Apr 15th, 2024 11:17PM Apr 16th, 2024 11:00AM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 15th, 2024 12:00AM FibroGen, Inc. 15K 431.00 Open Apr 14th, 2024 11:13PM Apr 15th, 2024 04:41PM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 14th, 2024 12:00AM FibroGen, Inc. 15K 432.00 Open Apr 13th, 2024 11:02PM Apr 13th, 2024 11:02PM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 13th, 2024 12:00AM FibroGen, Inc. 15K 432.00 Open Apr 12th, 2024 10:53PM Apr 13th, 2024 11:28AM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology
nasdaq:fgen 163793 Apr 12th, 2024 12:00AM FibroGen, Inc. 15K 433.00 Open Apr 11th, 2024 10:58PM Apr 12th, 2024 08:23AM We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers. Open Anemia, Chronic Kidney Disease, Fibrotic Disease, Duchenne Muscular Dystrophy, Pancreatic Cancer, HIF-PHI, and Anti-CTGF Open 409 Illinois St San Francisco CA US 94158 FibroGen Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.